PLB1004 plus chemo for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug (PLB1004) combined with two chemotherapy drugs for people with a specific EGFR gene change in their non-small cell lung cancer. The goal is to see if this combination works better than current treatments, both for advanced cancer and for cancer that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery, and it must have a specific EGFR gene change (mutation).
- You must be healthy enough to perform daily activities (ECOG score 0 or 1) and have a life expectancy of at least 12 weeks.
- You must have had some prior treatment, such as an EGFR-targeted pill (like osimertinib) or chemotherapy, unless you are in a part of the study that allows no prior treatment.
- Your organ function (like bone marrow, liver, kidneys, and heart) must be fairly good, as checked by blood tests.
- You cannot have certain medical conditions, such as uncontrolled high blood pressure, active infections, or heart rhythm problems.
- For those who have brain tumors (metastases), you must not have symptoms from them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This trial tests a combination of two experimental drugs (vebreltinib plus PLB1004) against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR mutation positive, MET positive) that has gotten worse after prior EGFR-targeted therapy.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.